drugset / Trial / NCT03119701

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA

NCT03119701

Phase 2 Terminated 40 enrolled Faron Pharmaceuticals Ltd
RandomizedParallel-groupQuadruple-blindPrevention

Summary

A study to assess effectiveness and safety of a drug FP-1201-lyo (Recombinant Human Interferon Beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic Aneurysm

Timeline

Start
2017-02-18
Primary completion
2019-09-23
Completion
2019-10-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon beta-1a Protein / enzyme biologic 10 ug Intravenous